本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第六届监事会 2025 年第一次会议于 2025 年 6 月 26 日（星期四）11:30 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2025 年 6 月 20 日 以电子邮件方式发出。会议应出席监事 3 名，实际出席监事 3 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。本次会议由全体监事推选周纯女士 主持，出席会议的监事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《关于选举公司第六届监事会主席》的议案 深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-030 深圳市理邦精密仪器股份有限公司 第六届监事会 2025年第一次会议决议公告 深圳市理邦精密仪器股份有限公司 监事会 二〇二五年六月二十七日 1 公司 2024 年度股东大会选举汪洪潮先生、周奕荣女士为公司第六届监事会 非职工代表监事，与职工代表监事周纯女士共同组成公司第六届监事会。根据《公 司 ...

公司 2024 年度股东大会选举产生了公司第六届董事会，根据《公司法》及 《公司章程》等有关规定，董事会同意选举张浩先生为公司第六届董事会董事长， 任期三年，自本次董事会审议通过之日起至公司第六届董事会届满为止。 证券代码：300206 证券简称：理邦仪器 公告编号：2025-029 深圳市理邦精密仪器股份有限公司 第六届董事会 2025 年第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第六届董事会 2025 年第一次会议于 2025 年 6 月 26 日（星期四）10:00 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2025 年 6 月 20 日 以电子邮件方式发出。会议应出席董事 7 名，实际出席董事 7 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。本次会议由全体董事推选张浩先生 主持，出席会议的董事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《关于选举公司第六届董事会董事长》的议案 深圳市理邦精密仪器股份有限公司 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of the company, Libang Instruments, within the medical device industry, noting its stock price increase and market capitalization [1] - As of June 23, the stock price of Libang Instruments closed at 11.53 yuan, reflecting a 3.87% increase, with a rolling PE ratio of 35.42 times and a total market value of 6.684 billion yuan [1] - The average PE ratio for the medical device industry is 48.89 times, with a median of 35.79 times, positioning Libang Instruments at the 75th rank within the industry [1][2] Group 2 - The company reported a revenue of 420 million yuan for Q1 2025, showing a year-on-year decrease of 5.25%, while net profit reached 65.0882 million yuan, marking a significant increase of 68.98% [1] - The gross profit margin for the company stands at 58.34%, indicating a strong profitability despite the decline in revenue [1] - The main business of Libang Instruments includes the research, production, sales, and service of medical electronic devices and in vitro diagnostic products, with a diverse range of offerings [1]

Group 1 - The medical device sector experienced a short-term surge, with Nanwei Co., Ltd. (603880) hitting the daily limit, and other companies like Haooubo, Shuoshi Bio, Zhengchuan Co., Ltd. (603976), Rejing Bio, and Libang Instruments (300206) also seeing significant gains [1] - The National Medical Products Administration approved measures to optimize the lifecycle regulation to support the innovation and development of high-end medical devices [1]

Core Viewpoint - The article highlights the resilience and innovative vitality of China's scientific instrument industry in the face of global challenges, showcasing significant growth in overseas revenue among domestic listed companies [2][6]. Group 1: Overview of Overseas Revenue - In 2024, the total overseas revenue of 43 domestic listed instrument companies reached 34.707 billion yuan, marking a new high [6][10]. - Over 60% of the companies reported revenue growth, with 21 companies achieving over 100 million yuan in overseas revenue [6][10]. - The top five companies by overseas revenue are Mindray Medical (16.434 billion yuan), Sunny Optical (9.602 billion yuan), Libang Instruments (1.098 billion yuan), BGI Genomics (913 million yuan), and Huashengchang (717 million yuan) [3][6]. Group 2: Performance Analysis - Among the 43 companies, 27 experienced stable or significant growth, with notable examples including Wanyi Technology, which saw a 447.23% increase in overseas revenue [7][12]. - Conversely, 14 companies faced revenue declines, such as Gaode Infrared, which reported a 50.76% drop [7][15]. - Mindray Medical's overseas revenue accounted for 44.75% of its total revenue, reflecting the effectiveness of its globalization strategy [10][17]. Group 3: Market Dynamics - The article indicates a shift in the market, with three companies achieving over 1 billion yuan in overseas revenue, while 18 companies fall within the 100 million to 1 billion yuan range [13]. - Companies with overseas revenue constituting over 10% of total revenue increased to 22, indicating a growing trend in international market engagement [17]. - Wanyi Technology's strategy of "product leadership, quality excellence, competitive pricing, and superior service" has led to substantial growth in overseas markets [13][17]. Group 4: Emerging Companies - New entrants like Titan Technology and Lihua Technology reported 100% growth in overseas revenue, reflecting successful market expansion strategies [14]. - Titan Technology leveraged partnerships with overseas distributors and acquisitions to enhance its competitive brand presence [14]. Group 5: Future Outlook - Despite external uncertainties, the overall trend indicates a robust commitment from Chinese companies to expand in international markets, suggesting a "fast forward" approach to globalization [17].

Company Overview - Shenzhen Lifetech Scientific Corporation specializes in the research, development, production, sales, and service of medical electronic devices and in vitro diagnostic products [1] - The main products include critical care monitoring solutions, bedside monitoring solutions, intelligent vital signs management solutions, and various ultrasound diagnostic systems [1] Financial Performance - For Q1 2025, the company reported revenue of 420 million yuan, a year-on-year decrease of 5.25% [1] - The net profit for the same period was 65.09 million yuan, showing a year-on-year increase of 68.98% [1] - The gross profit margin stood at 58.34% [1] Market Position - As of June 3, the closing price of the stock was 11.89 yuan, reflecting an increase of 2.68% [1] - The rolling price-to-earnings (PE) ratio is 36.53, while the average PE ratio for the medical device industry is 50.80 [2] - The company's total market capitalization is 6.892 billion yuan [1][2] Institutional Holdings - As of Q1 2025, there are 2 institutions holding shares in the company, with a total of 48.78 million shares valued at 591 million yuan [1]

Core Viewpoint - The company is focusing on business expansion and operational efficiency to recover from a significant revenue decline in 2024, with optimistic projections for 2025 growth [2][4]. Group 1: Company Performance and Plans - As of May 23, 2025, the company's stock price is 11.6 yuan, down 1.36% from the previous week, with a total market capitalization of 6.724 billion yuan [1]. - The company plans to deepen its domestic market presence and expand internationally, while accelerating the market layout of high-tech products [1]. - The second phase of the industrial building project is expected to be completed by the end of 2025, with the current construction phase involving basement work and mechanical installations [1]. - The profit distribution plan for 2024 has been approved by the shareholders' meeting and will be executed promptly after necessary approvals [1][4]. Group 2: Market Conditions and Challenges - The company experienced an 82% year-on-year revenue decline in 2024 due to industry policy adjustments and economic changes, but is optimistic about domestic sales growth in 2025 [2][4]. - The company has implemented measures to optimize personnel, market strategies, and channel management in response to market changes [2]. - The company has maintained an average of about 10% of its total revenue from the U.S. market, indicating limited impact from international trade challenges [2]. - The global medical device market is projected to grow from $629.2 billion in 2024 to $743.2 billion by 2027, with a compound annual growth rate of 5.71% [3].

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-028 深圳市理邦精密仪器股份有限公司 2024年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、深圳市理邦精密仪器股份有限公司（以下简称"公司"） 2024 年度权益 分派方案为：以公司现有总股本 579,663,346 股为分配基数，向股权登记日登记 在册的全体股东每 10 股派发现金股利人民币 2.07 元（含税），合计派发现金股 利人民币 119,990,312.62 元（含税），不送红股，不以资本公积金转增股本，剩余 未分配利润结转以后年度分配。 2、本次权益分派方案自披露至实施期间，公司股本总额未发生变化。 3、本次权益分派实施后的除权除息价格（元/股）=股权登记日收盘价- 0.2070000 元/股。 公司 2024 年年度权益分派方案已获 2025 年 5 月 15 日召开的 2024 年度股东 大会审议通过，现将有关事项公告如下： 一、 股东大会审议通过利润分配方案情况 1、公司2024年度股东大会审议通过的20 ...

5月20日，理邦仪器今日收盘11.92元，上涨1.19%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到36.62倍，总市值69.10亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入4.20亿元，同比-5.25%；净利润6508.82万元，同 比68.98%，销售毛利率58.34%。 截至2025年一季报，共有2家机构持仓理邦仪器，其中其他2家，合计持股数4877.75万股，持股市值5.91 亿元。 深圳市理邦精密仪器股份有限公司的主营业务是从事医疗电子设备产品和体外诊断产品的研发、生产、 销售、服务。公司的主要产品是急危重症监护方案、床旁监护方案、智能生命体征查房方案、静态心 电、运动心电、动态心电/血压、心电网络解决方案、推车式全数字彩色超声诊断系统、便携式全数字 彩色超声诊断系统、全数字超声诊断系统、手持式超声诊断系统、围产监护方案、妇科诊疗方案、盆底 康复方案、血气分析仪、采血器、软件管理产品、磁敏荧光免疫分析仪、血细胞分析仪、分子诊断产 品、智慧健康业务。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.51倍，行业中值36.17倍，理邦仪器排 名第76位。 来 ...

深圳市理邦精密仪器股份有限公司 投资者关系活动记录表 | 投资者关 | □特定对象调研 □分析师会议 | | --- | --- | | 系活动类 | □媒体采访 ■业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位 | | | 名称及人 | 线上参与公司 2024 年度网上业绩说明会的全体投资者 | | 员姓名 | | | 时间 | 2025 年 5 月 19 日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 上市公司 | 董事长、总裁：张浩 | | 接待人员 | 董事、副总裁、董事会秘书、财务负责人：祖幼冬 | | 姓名 | 独立董事：郑全录 | | | 1、请问公司领导，目前的业务增长情况如何？未来有哪些具体的市场扩展 | | 投资者关 | 计划？ | | 系活动主 | 公司目前经营状况正常，各项业务按计划有序推进，具体经营数据和业务信 | | 要内容介 | 息请参考公司定期披露的公告。 关于未来市场拓展，一方面，公司将继续深耕 | | 绍 | 国内市场和夯实国内基础，挖掘潜在 ...